Advances in skin aging: integrating epigenetic, cellular, and immune mechanisms for targeted therapy Authors: Jinxuan Su, Hongzhong Jin Published: 2026 ABSTRACT As the largest and most externally exposed organ, the skin is particularly vulnerable to aging, rendering skin aging a widespread clinical and aesthetic concern. Driven by both intrinsic and extrinsic factors, skin aging is characterized by progressive functional decline and structural remodeling that compromise barrier integrity, disrupt dermal homeostasis, and ultimately diminish quality of life. At the upstream regulatory level, skin aging-associated epigenetic modifications drive epigenetic drift that compromises transcriptional fidelity and primes cells toward senescence. At the cellular level, regulatory mechanisms converge on cellular senescence and profound mitochondrial remodeling. At the microenvironmental level, the failure of senescent cell clearance (immunosenescence) and the emergence of a chronic pro-inflammatory milieu (inflammaging) create a self-reinforcing immune–inflammatory axis. This axis exacerbates cytokine production, extracellular matrix remodeling, and progressive tissue degeneration. We further highlight emerging mechanism-targeted interventions, including epigenetic and mitochondrial modulators, senotherapeutics, biologics, immunotherapies, regenerative and device-based therapies. A deeper understanding of these interconnected molecular mechanisms and targeted therapies may offer a roadmap for future therapeutic innovation and translational research in skin aging. Introduction The skin, the body’s largest organ, serves as the primary barrier against environmental insults. Skin aging is a multifactorial process driven by both intrinsic and extrinsic factors [1], manifesting as wrinkles, loss of elasticity, pigmentary changes, and barrier dysfunction, all of which impact quality of life [2]. Despite extensive advances in skin aging research, mechanistic studies have predominantly focused on discrete processes such as epigenetic alterations, cellular senescence, mitochondrial dysfunction, inflammaging, and immunosenescence as critical drivers of skin aging. Epigenetic drift stabilizes senescence-associated transcriptional programs, leading to cell senescence and subcellular mitochondrial dysfunction in the skin [3]. Accumulation of senescent cells and their pro-inflammatory secretome triggers inflammaging, a chronic, low-grade systemic inflammation, accompanied by the release of inflammatory cytokines such as IL-6, IL-8, and TNF-α [4]. Immunosenescence reflects decreased immune function with age and subsequently compromises surveillance and fails to efficiently clear senescent cells [5]. However, how these processes are mechanistically interconnected across molecular, cellular, and microenvironmental levels in the whole scenario of skin aging remains incompletely understood. Here, we integrate recent advances and propose a comprehensive scenario of skin aging. By delineating the mechanistic crosstalk, we highlight emerging mechanism-guided therapeutic strategies, including epigenetic interventions, senotherapies, mitochondrial modulation, biologics, immunotherapies, and regenerative and device-assisted approaches for anti-skin aging. Through this integrative perspective, we aim to provide novel conceptual and therapeutic insights for mitigating age-related skin degeneration and promoting rejuvenation. Intrinsic and extrinsic skin aging Skin aging, a multifaceted biological process, comprises two interrelated yet mechanistically distinct processes: intrinsic aging and extrinsic aging [1]. Intrinsic aging, also known as chronological aging, results from internal genetic and metabolic processes, including telomere attrition, epigenetic drift and stem-cell exhaustion. [6, 7]. Extrinsic aging is primarily induced by environmental exposures, particularly ultraviolet (UV) radiation, pollution, smoking, and exposome-associated oxidative stress, with photoaging representing its most prominent manifestation [7–9]. Phenotypically, intrinsic aging and extrinsic aging share both different and overlapping features. Both processes contribute to wrinkle formation, loss of elasticity, hair and pigmentation alterations, and impaired barrier function, collectively compromising skin homeostasis and quality of life [2]. However, intrinsic aging is typically associated with fine wrinkles, epidermal thinning, and gradual tissue atrophy, whereas extrinsic aging is characterized by coarse wrinkles, uneven pigmentation (age spots), and uneven tone [8]. Histologically, both intrinsic and extrinsic aging converge on common structural alterations, including reduced dermal collagen synthesis, fibroblast functional decline, stem cell exhaustion, and impaired melanogenesis [10–12]. In extrinsic aging, these changes are more pronounced and are additionally accompanied by solar elastosis and severe extracellular matrix degradation. These processes collectively culminate in diminished skin resilience, compromised barrier integrity, and reduced capacity for repair and hydration. Importantly, emerging evidence indicates substantial crosstalk between intrinsic and extrinsic aging pathways. UV exposure accelerates intrinsic aging hallmarks by increasing reactive oxygen species (ROS) production, enhancing matrix metalloproteinase (MMP) activity, and promoting senescence-associated secretory phenotype (SASP), thereby accelerating epigenetic aging and dermal degeneration. Conversely, intrinsic aging-related immunosenescence and reduced antioxidant capacity increase susceptibility to environmental damage, amplifying photoaging responses (Table 1).Table 1Mechanistic differences between intrinsic and extrinsic skin agingFeatureIntrinsic aging (chronological)Extrinsic aging (photoaging)Primary driversTelomere shortening, epigenetic drift, stem cell exhaustionUV radiation, pollution, smoking, oxidative stressKey signalingDNA damage response, senescence accumulationROS–NF-κB, MAPK, AP-1 activationECM changesGradual collagen decline, reduced fibroblast activityMMP-driven collagen degradation, elastosisInflammationLow-grade chronic inflammation (inflammaging)Strong SASP-like inflammatory activationPigmentationMild hypopigmentation/heterogeneityHyperpigmentation, age spotsClinical featuresFine wrinkles, thinning skinDeep wrinkles, rough texture, dyschromia Table 1Mechanistic differences between intrinsic and extrinsic skin agingFeatureIntrinsic aging (chronological)Extrinsic aging (photoaging)Primary driversTelomere shortening, epigenetic drift, stem cell exhaustionUV radiation, pollution, smoking, oxidative stressKey signalingDNA damage response, senescence accumulationROS–NF-κB, MAPK, AP-1 activationECM changesGradual collagen decline, reduced fibroblast activityMMP-driven collagen degradation, elastosisInflammationLow-grade chronic inflammation (inflammaging)Strong SASP-like inflammatory activationPigmentationMild hypopigmentation/heterogeneityHyperpigmentation, age spotsClinical featuresFine wrinkles, thinning skinDeep wrinkles, rough texture, dyschromia Mechanistic differences between intrinsic and extrinsic skin aging Upstream epigenetic regulatory mechanisms of skin aging As the body’s primary defense against environmental insults, the skin undergoes substantial environmental-driven aging changes. Epigenetic regulation, acting as a dynamic sensor and responder between external stressors and genomic responses, orchestrates the trajectory of skin aging and reshapes the transcriptional landscape without altering DNA sequences (Fig. 1).Fig. 1Epigenetic alterations, cellular senescence, and mitochondrial dysfunction in skin aging. Epigenetic alterations act as key upstream regulators of skin aging, integrating metabolic and environmental signals through mechanisms including N6-methyladenosine (m6A) modification, histone modifications and variants, lactylation, and non-coding RNA-mediated regulation. These changes promote cellular senescence, characterized by increased p16INK4a, p21CIP1, p53, and SA-β-Gal activity, reduced Lamin B1 expression, and irreversible cell-cycle arrest. Senescent cells exhibit mitochondrial dysfunction, including mtDNA damage, impaired PINK1/Parkin-mediated mitophagy, defective mitochondrial quality control, reduced oxidative phosphorylation and ATP production, loss of mitochondrial membrane potential, and excessive reactive oxygen species (ROS) generation. Together, these alterations disrupt tissue homeostasis and contribute to skin aging. The schematic illustration was created using BioRender (https://www.biorender.com/) Epigenetic alterations, cellular senescence, and mitochondrial dysfunction in skin aging. Epigenetic alterations act as key upstream regulators of skin aging, integrating metabolic and environmental signals through mechanisms including N6-methyladenosine (m6A) modification, histone modifications and variants, lactylation, and non-coding RNA-mediated regulation. These changes promote cellular senescence, characterized by increased p16INK4a, p21CIP1, p53, and SA-β-Gal activity, reduced Lamin B1 expression, and irreversible cell-cycle arrest. Senescent cells exhibit mitochondrial dysfunction, including mtDNA damage, impaired PINK1/Parkin-mediated mitophagy, defective mitochondrial quality control, reduced oxidative phosphorylation and ATP production, loss of mitochondrial membrane potential, and excessive reactive oxygen species (ROS) generation. Together, these alterations disrupt tissue homeostasis and contribute to skin aging. The schematic illustration was created using BioRender (https://www.biorender.com/) DNA methylation, hydroxymethylation, and epigenetic drift Age-associated shifts in DNA methylation, collectively referred to as the “epigenetic clock”, particularly at loci regulating epidermal differentiation and innate immune responses in both epidermal cells and T cells [13]. DNA methylation is mediated by DNA methyltransferases (DNMTs), typically resulting in transcriptional repression. DNMT1 is highly expressed in basal-layer epidermal progenitor stem cells, where it is indispensable for lineage commitment and differentiation [14]. Silencing DNMT1 in young fibroblasts accelerates cellular senescence, suggesting its critical role in maintaining dermal cell vitality. Moreover, epidermis-specific deletion of DNMT1 in mice activates cGAS-STING signaling, inducing chronic inflammation, disruption of epidermal structure, and extensive immune infiltration [15]. DNA hydroxymethylation refers to the conversion of 5-methylcytosine (5-mC) into 5-hydroxymethylcytosine (5-hmC), a reaction catalyzed by the Ten-Eleven Translocation (TET) enzyme family, leading to transcriptional reactivation and maintaining skin epigenomic plasticity. TET2 is frequently hypermethylated and transcriptionally repressed in aged epidermal tissues, indicating its decline with advancing age [16]. Notably, activation of the SIRT4/TET2 axis mitigates keratinocyte senescence by restoring 5-hmC levels, suggesting a potential therapeutic strategy to counteract age-related epigenetic drift [16]. Clinically, recent advances in epigenetic clocks have provided powerful tools for assessing biological skin aging beyond chronological age alone. These clocks capture age-associated methylation drift that reflects the cumulative effects of intrinsic aging and environmental stressors on cutaneous tissues [17]. Importantly, skin-specific methylation clocks correlate with clinically relevant aging phenotypes, including wrinkle formation, facial aging, and photoaging-associated epigenomic alterations [18]. Several epigenetic clock models, including Skin & Blood, VisAgeX, and PhenoAge, have been applied to estimate biological skin age and age-related epigenetic changes [19, 20]. More recently, minimally invasive epidermal methylation clocks based on tape-stripping approaches have improved the feasibility of longitudinal skin aging assessment [21]. These tools provide quantitative biomarkers for evaluating biological skin age, tracking aging trajectories, and monitoring responses to rejuvenation interventions, highlighting their growing translational relevance in dermatology. Histone modifications Histone modifications, including acetylation, methylation, and lactylation, serve as dynamic regulators of chromatin architecture and gene transcription, thereby shaping cellular functions and aging trajectories, whose dysregulation leads to transcriptional dysregulation, compromised skin integrity, and hallmark phenotypes of cutaneous aging. Histone methylation exerts context-dependent effects on gene activity. In the epidermis, proliferative basal cells exhibit high levels of H3K4me3, H4K20me1, and H4K16ac, supporting active transcription and renewal, while differentiated suprabasal cells accumulate repressive marks H3K27me3 and H4K20me3 along with reduced H4K16 acetylation, reflecting transcriptional repression during terminal differentiation [22]. Age-associated disruption of these histone modification patterns may impair epidermal renewal and alter differentiation programs, leading to progressive deterioration of epidermal function. Collectively, these findings suggest that disruption of histone modification patterns during aging may impair epidermal homeostasis and differentiation, thereby contributing to skin aging-associated phenotypes such as impaired barrier integrity and reduced regenerative capacity. Histone variant represents a critical epigenetic mechanism influencing chromatin structure in skin aging. Increased accumulation of the histone variant H2A.J has been identified both in aged epidermis and dermal fibroblasts and enhances SASP, serving as a novel biomarker of skin aging [23]. Altered expression of histone deacetylases (HDACs) constitutes another hallmark of both photoaged and intrinsically aged skin. HDAC4 and HDAC11 are consistently downregulated under UV exposure and chronological aging [24]. Functionally, HDAC4 modulates DNA damage-inducible transcript 4 (DDIT4), a key senescence-associated factor. Restoration of HDAC4 expression rescues DDIT4 levels and mitigates senescence, suggesting a protective role of HDAC4 in epidermal aging [25]. Emerging evidence has identified lactylation, a lactate-derived lysine modification, as a novel metabolic–epigenetic mechanism involved in skin aging [26]. Given that progressive collagen loss is a hallmark of aged skin, recent studies suggest that lactylation may alleviate age-related dermal deterioration by promoting collagen synthesis. In dermal fibroblasts, extracellular lactate is transported via MCT1 and induces KAT8-mediated lactylation of latent transforming growth factor-β binding protein 1 (LTBP1) at lysine 752, thereby enhancing TGF-β activation and increasing COL1A1 and COL3A1 expression [27]. In addition, lactate can indirectly stimulate collagen production through macrophage–fibroblast crosstalk. Lactate-induced H4K12 lactylation in macrophages, mediated by KAT5/KAT8, enhances TGF-β1 and TGF-β3 transcription, which subsequently promotes collagen synthesis in neighboring fibroblasts. Notably, a feedback loop between H4K12 lactylation and HDAC3 regulates this process and maintains lactylation homeostasis [28]. Collectively, these findings suggest that lactylation links cellular metabolism to extracellular matrix maintenance and may represent a promising epigenetic target for preventing collagen loss and mitigating skin aging. Collectively, dysregulated histone modifications drive chromatin remodeling, disrupt epidermal homeostasis, and reinforce the proinflammatory milieu characteristic of aged skin. Non-coding RNAs (ncRNAs) and epitranscriptomic plasticity Beyond DNA methylation and histone modifications, non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), also represent a key regulator of epigenetic regulation in skin aging [29]. They alter gene expression by modulating mRNA stability, translation efficiency, and chromatin remodeling. Recent evidence indicates that specific ncRNAs orchestrate skin aging by regulating senescence, oxidative stress, and tissue repair. miR-217 is markedly upregulated in aged skin, driving senescence and attenuating regenerative potential [30]. Moreover, overexpression of miR-217, miR-30, miR-200, and miR-181 families promotes senescence through disrupted autophagic clearance, elevated oxidative damage and ROS levels, and reduced SIRT1-dependent mitochondrial homeostasis, respectively [31, 32]. Conversely, miR-146a expression declines with age, disrupting circadian rhythm regulation, reducing collagen synthesis and proliferation, and enhancing inflammation and genomic instability [33]. In photoaging and UV-induced premature senescence, the miR-23a–AMBRA1 pathway modulates autophagy and cellular quality control [34], whereas the miR-15b–SIRT4 axis regulates mitochondrial ROS homeostasis and oxidative stress resilience [35]. LncRNAs interact with miRNAs and target mRNAs, forming complex lncRNA-miRNA-mRNA networks that integrate DNA damage responses, inflammation, and matrix homeostasis [36]. For instance, RP11-670E13.6 is upregulated in UVB-irradiated primary human dermal fibroblasts (HDF), enhancing ATM and γH2A.X signaling to delay senescence via the RP11-670E13.6-miR-663a-CDK4/CDK6 axis, thereby facilitating DNA damage repair and mitigating UVB radiation-induced senescence [37]. Conversely, the Meg3-miR-93-5p-epiregulin pathway amplifies UVB-induced inflammation [38], while SPRR2C modulates calcium gradients and miRNA sequestration during epidermal aging [39]. The H19-miR-296-5p-IGF2 [40] and PVT1-miR-551b-3p-AQP3 [41] circuits regulate fibroblast senescence and photoaging, respectively, linking ncRNA crosstalk to extracellular matrix (ECM) maintenance and barrier function. Collectively, these ncRNA-mediated circuits highlight a multilayered post-transcriptional network that drives intrinsic and extrinsic skin aging and highlight their translational promise in combating skin aging. N6-methyladenosine (m6A) N6-methyladenosine (m6A) RNA methylation, the most prevalent internal mRNA modification, regulates RNA stability, splicing, translation, export, and degradation. Global m6A levels decline with age, reflecting an epitranscriptomic drift associated with the aging phenotype [42]. Emerging evidence implicates m6A dysregulation in skin aging, particularly in photoaging and dermal fibroblast senescence. WTAP-mediated m6A modification promotes fibroblast senescence and SASP activation through the ELF3/IRF8 pathway [43]. Similarly, UVB-induced photoaging is associated with extensive m6A remodeling, in which elevated METTL3 and METTL14 enhance fibroblast senescence and inflammatory responses through multiple downstream targets [44]. In addition, METTL14-mediated maturation of miR-100-3p suppresses ERRFI1 expression and accelerates UVB-induced fibroblast photoaging [45] (Table 2).Table 2Key Epigenetic Mechanisms in Skin AgingEpigenetic changesMechanismsClinical/Phenotypic manifestationsReferencesDNA methylation/hydroxymethylation DNMT1DNMT1 deficiency activates cGAS–STING signaling, induces epidermal inflammation, and disrupts epidermal architectureEpidermal barrier dysfunction, chronic inflammation, impaired epidermal homeostasis [15] TET2Age-associated TET2 downregulation reduces 5-hmC levels and promotes keratinocyte senescenceKeratinocyte senescence and impaired epidermal regeneration [16, 46]Histone modifications HDAC4HDAC4 overexpression reverses fibroblast senescence through DDIT4-dependent signalingDermal fibroblast senescence, SASP, and impaired dermal homeostasis [25] HDAC11Reduced HDAC11 expression in intrinsically aged and UV-irradiated skinIntrinsic aging and photoaging [24] H2A.J variantPromotes senescence-associated chromatin remodeling and SASP activationKeratinocyte senescence, impaired epidermal renewal, and epidermal thinning [23, 47] LTBP1 lactylationKAT8-mediated lactylation enhances TGF-β activation and collagen synthesisCollagen loss, ECM deterioration, and skin rejuvenation deficit [27] H4K12laMacrophage-derived histone lactylation stimulates TGF-β-mediated fibroblast activationCollagen loss, ECM deterioration [48]Non-coding RNAs (miRNAs, lncRNAs) miR-217Targets DNMT1 and promotes fibroblast senescenceFibroblast senescence, barrier dysfunction, and keratinocyte apoptosis [30–33] miR-30aRegulates epidermal differentiation and barrier-associated pathwaysEpidermal thinning and impaired barrier integrity [31, 37, 38, 40, 41, 49] miR-200aSuppresses OGG1-mediated oxidative DNA repair in keratinocytesOxidative DNA damage accumulation, and inflammaging [32] miR-146aModulates inflammatory and senescence-associated pathwaysReduced collagen production, chronic low-grade inflammation and inflammaging [33] miR-23a/miR-15bRegulate autophagy impairment and mitochondrial ROS productionPremature senescence and SASP amplification, photoaging [34, 35] RP11-670E13.6Delays UVB-induced fibroblast senescence via miRNA spongingProtection against UV-induced photoaging [37] Meg3Activates inflammatory injury through the miR-93-5p/epiregulin axisExacerbation of UVB-induced skin inflammation [38] H19Suppresses fibroblast senescence through IGF2/SIRT1-associated pathwaysReduced fibroblast senescence [40, 49] PVT1Regulates AQP3 expression via ceRNA signalingImproved skin hydration and delayed photoaging [41]N6-methyladenosine (m6A) METTL14Regulates DGCR8-dependent maturation of miR-100-3p and suppresses ERRFI1 expressionUVB-induced fibroblast senescence and photoaging [45] WTAPActivates the m6A-dependent ELF3/IRF8 axis and promotes SASP signalingFibroblast senescence and SASP [43] Table 2Key Epigenetic Mechanisms in Skin AgingEpigenetic changesMechanismsClinical/Phenotypic manifestationsReferencesDNA methylation/hydroxymethylation DNMT1DNMT1 deficiency activates cGAS–STING signaling, induces epidermal inflammation, and disrupts epidermal architectureEpidermal barrier dysfunction, chronic inflammation, impaired epidermal homeostasis [15] TET2Age-associated TET2 downregulation reduces 5-hmC levels and promotes keratinocyte senescenceKeratinocyte senescence and impaired epidermal regeneration [16, 46]Histone modifications HDAC4HDAC4 overexpression reverses fibroblast senescence through DDIT4-dependent signalingDermal fibroblast senescence, SASP, and impaired dermal homeostasis [25] HDAC11Reduced HDAC11 expression in intrinsically aged and UV-irradiated skinIntrinsic aging and photoaging [24] H2A.J variantPromotes senescence-associated chromatin remodeling and SASP activationKeratinocyte senescence, impaired epidermal renewal, and epidermal thinning [23, 47] LTBP1 lactylationKAT8-mediated lactylation enhances TGF-β activation and collagen synthesisCollagen loss, ECM deterioration, and skin rejuvenation deficit [27] H4K12laMacrophage-derived histone lactylation stimulates TGF-β-mediated fibroblast activationCollagen loss, ECM deterioration [48]Non-coding RNAs (miRNAs, lncRNAs) miR-217Targets DNMT1 and promotes fibroblast senescenceFibroblast senescence, barrier dysfunction, and keratinocyte apoptosis [30–33] miR-30aRegulates epidermal differentiation and barrier-associated pathwaysEpidermal thinning and impaired barrier integrity [31, 37, 38, 40, 41, 49] miR-200aSuppresses OGG1-mediated oxidative DNA repair in keratinocytesOxidative DNA damage accumulation, and inflammaging [32] miR-146aModulates inflammatory and senescence-associated pathwaysReduced collagen production, chronic low-grade inflammation and inflammaging [33] miR-23a/miR-15bRegulate autophagy impairment and mitochondrial ROS productionPremature senescence and SASP amplification, photoaging [34, 35] RP11-670E13.6Delays UVB-induced fibroblast senescence via miRNA spongingProtection against UV-induced photoaging [37] Meg3Activates inflammatory injury through the miR-93-5p/epiregulin axisExacerbation of UVB-induced skin inflammation [38] H19Suppresses fibroblast senescence through IGF2/SIRT1-associated pathwaysReduced fibroblast senescence [40, 49] PVT1Regulates AQP3 expression via ceRNA signalingImproved skin hydration and delayed photoaging [41]N6-methyladenosine (m6A) METTL14Regulates DGCR8-dependent maturation of miR-100-3p and suppresses ERRFI1 expressionUVB-induced fibroblast senescence and photoaging [45] WTAPActivates the m6A-dependent ELF3/IRF8 axis and promotes SASP signalingFibroblast senescence and SASP [43] Key Epigenetic Mechanisms in Skin Aging Although current evidence linking m6A to skin aging remains limited, available studies suggest that m6A-mediated epitranscriptomic remodeling contributes to photoaging-associated skin dysfunction, largely through regulation of dermal fibroblast senescence and inflammatory signaling. However, fibroblast aging represents only one component of skin aging, which involves coordinated alterations across multiple cell types, including keratinocytes, melanocytes, immune cells, and stem cell populations. Future studies are needed to define the cell type-specific and spatial functions of m6A regulators in intrinsic and extrinsic skin aging. Cellular level mechanisms of skin aging Cellular senescence and mitochondrial remodeling Cellular senescence, the core mechanism of skin aging, particularly in dermal fibroblasts and epidermal keratinocytes, is characterized by classical hallmarks such as sustained p53/p21 activation, context-dependent engagement of the p16INK4a–RB axis, senescence-associated β-galactosidase (SA-β-Gal) activity, and loss of Lamin B1, typically arising from genomic instability or chronic ultraviolet exposure [50]. Increasing evidence indicates that this senescent state is not solely dictated by nuclear damage but is actively executed and stabilized through metabolic and mitochondrial remodeling. The skin is exceptionally vulnerable to mitochondrial dysfunction due to continuous environmental insults and high metabolic demands required for rapid tissue turnover. Keratinocytes and fibroblasts rely heavily on mitochondrial ATP generation, NAD+ homeostasis, and lipid metabolism, while mitochondrial DNA lacks histone protection and exhibits limited repair capacity. As a consequence, mitochondrial membrane potential disruption, impaired oxidative phosphorylation, accumulation of mtDNA mutations, and excessive ROS production converge to establish a self-amplifying metabolic loop that enforces senescence rather than merely accompanying it [51]. This amplification cycle drives cellular senescence and ECM degradation, ultimately contributing to manifestations like wrinkles, dryness, and elasticity loss [52]. Mitochondrial damage acts as a triggering source of inflammatory activation or inflammaging. mtDNA depletion induces a SASP with increased IL-28a, IFN-β1, COX2, NF-κB, and CCL5 in both the epidermis and dermis, reinforcing inflammaging and tissue degeneration [53]. Mitochondrial quality control pathways are essential for maintaining cutaneous homeostasis. Calcium imbalance mediated by TRP channels (e.g., TRPV1, TRPM7) triggers Δψm decline, ROS accumulation, MMP-1 induction, and nuclear enlargement, thereby accelerating senescence and wrinkle formation [54, 55]. Antioxidant defenses such as SOD3 counteract ROS-driven ECM degradation and aging manifestations by suppressing NF-κB/MAPK activation and restoring collagen synthesis [56]. Multiple mitochondrial regulators operate as protective mechanisms yet decline during aging. Reduced ANT2 weakens ATP transport and enhances inflammation, while its restoration in fibroblasts improves mitochondrial function and wound healing [57]. Stress-responsive mitokines including GDF15 and lipid-associated proteins such as PLIN2 preserve mitochondrial stability and prevent senescence, indicating strong crosstalk between mitochondrial metabolism, lipid homeostasis, and skin aging [58, 59]. Mitophagy, the selective autophagic removal of damaged mitochondria, provides an additional safeguard for homeostasis. NIX-dependent mitophagy supports keratinocyte differentiation and reduces UV-induced senescence, whereas dysregulation of both PINK1/Parkin-dependent and independent (e.g., FUNDC1) pathways contribute to photodamage and metabolic decline [60–62]. Post-translational control such as neddylation further maintains autophagic flux and delays senescence by antagonizing the ubiquitin-mediated degradation of LC3B [63] (Table 3).Table 3Mitochondrial dysfunction in skin agingMitochondrial DysfunctionsKey Molecular regulatorsCellular ConsequencesClinical/Phenotypic ManifestationsReferenceMitochondrial membrane potential (Δψm)TRPV1, TRPM7Reduced ATP production, increased ROSWrinkling, impaired wound healing, keratinocyte senescence [54, 55]mtDNA damage & mutationsUV-induced ROS, lack of histone protectionMutation accumulation, impaired biogenesisPigmentation changes, elasticity loss, chronic inflammation [53, 64]Mitochondrial dynamics & mitophagyNIX, PINK1/Parkin, FUNDC1Defective clearance of damaged mitochondriaAccumulation of dysfunctional organelles, accelerated senescence [60–62]Mitokines & regulatorsGDF15, PLIN2, ANT2Stress response, lipid metabolism regulation, ATP importSASP secretion, delayed wound healing, fibroblast senescence [57–59]Antioxidant defenseSOD3, Mn-SODROS scavenging, ECM protectionReduced collagen degradation, preserved dermal integrity [56]Ca2+-dependent regulationTRP channels, mitochondrial Ca2+ uptakeAltered differentiation, ROS productionEpidermal thinning, photoaging [54, 55] Table 3Mitochondrial dysfunction in skin agingMitochondrial DysfunctionsKey Molecular regulatorsCellular ConsequencesClinical/Phenotypic ManifestationsReferenceMitochondrial membrane potential (Δψm)TRPV1, TRPM7Reduced ATP production, increased ROSWrinkling, impaired wound healing, keratinocyte senescence [54, 55]mtDNA damage & mutationsUV-induced ROS, lack of histone protectionMutation accumulation, impaired biogenesisPigmentation changes, elasticity loss, chronic inflammation [53, 64]Mitochondrial dynamics & mitophagyNIX, PINK1/Parkin, FUNDC1Defective clearance of damaged mitochondriaAccumulation of dysfunctional organelles, accelerated senescence [60–62]Mitokines & regulatorsGDF15, PLIN2, ANT2Stress response, lipid metabolism regulation, ATP importSASP secretion, delayed wound healing, fibroblast senescence [57–59]Antioxidant defenseSOD3, Mn-SODROS scavenging, ECM protectionReduced collagen degradation, preserved dermal integrity [56]Ca2+-dependent regulationTRP channels, mitochondrial Ca2+ uptakeAltered differentiation, ROS productionEpidermal thinning, photoaging [54, 55] Mitochondrial dysfunction in skin aging Heterogeneous senescent cell states and aging niches in the skin Beyond classical hallmarks, accumulating single-cell and spatial transcriptomic evidence has reshaped skin aging as a spatially organized and cell-type–specific process, rather than a uniform accumulation of senescent cells. Senescent fibroblasts preferentially localize near the dermal–epidermal junction, where they drive regional extracellular matrix disorganization and establish pro-aging inflammatory niches [65]. Single-cell analyses further reveal divergent senescence trajectories across skin cell types, with fibroblasts exhibiting the greatest transcriptional variability during aging [66]. Notably, aging is accompanied by a progressive loss of cellular identity and functional specialization across multiple skin cell populations [67]. Distinct fibroblast subpopulations gradually lose their lineage-specific transcriptional programs and “priming” states during aging, resulting in impaired secretory, mesenchymal, and tissue-supportive functions [68]. Spatial transcriptomic studies further demonstrate region-specific remodeling characterized by chronic inflammatory activation, metabolic reprogramming, and disruption of dermal–epidermal communication, indicating that deterioration of tissue architecture and signaling networks is a fundamental feature of skin aging [65, 69]. In particular, aging-associated reductions in epidermal fatty acid synthesis have emerged as an underappreciated mechanism linking metabolic dysfunction to keratinocyte senescence, barrier impairment, and epidermal aging [65]. Importantly, aging-related functional decline is not solely dictated by intrinsic cellular senescence but is strongly shaped by the surrounding niche. Hair follicle stem cells, despite numerical decline, retain lineage identity and regenerative capacity when placed in a youthful dermal microenvironment, whereas young stem cells fail within aged niches [70]. Similarly, senescent melanocytes exert non–cell-autonomous effects through ROS-inducing SASP, impairing basal keratinocyte proliferation and contributing to epidermal atrophy [71, 72]. Beyond epithelial and mesenchymal compartments, senescence in non-parenchymal cells such as endothelial cells actively initiates aging niches via neuroimmune signaling, further amplifying local inflammation and tissue degeneration [73]. Together, these findings establish that skin aging emerges from coexisting heterogeneous senescent cell states embedded within distinct molecular and spatial niches. Rather than representing isolated cellular dysfunction, skin aging is increasingly recognized as a multicellular process driven by dynamic interactions among senescent cells, metabolic remodeling, and disrupted intercellular communication within aging tissue microenvironments. These insights highlight the necessity for precision targeting of pathogenic senescent subsets rather than indiscriminate senescent cell elimination. Metabolic-epigenetic regulation of stem cell aging Accumulating evidence indicates that cellular metabolites function not only as energy substrates but also as epigenetic cofactors that link metabolism to chromatin organization, stem-cell fate, and tissue homeostasis. Age-associated alterations in metabolites such as acetyl-CoA [74], α-ketoglutarate [75], NAD+ [74], and S-adenosylmethionine [74] can directly influence histone acetylation, DNA/histone methylation, and chromatin accessibility, thereby reshaping transcriptional programs that maintain epidermal stem-cell identity and regenerative capacity. As these metabolic–epigenetic circuits become dysregulated during aging, stem cells progressively lose lineage fidelity and functional competence, contributing to impaired tissue repair and aberrant differentiation trajectories [76]. Beyond regulating cell fate, metabolic and genotoxic stress also influence clonal dynamics through stem-cell competition mechanisms. COL17A1-dependent fitness sensing eliminates damaged or less competitive stem cells to preserve epidermal integrity and genomic stability [77]. Age-associated disruption of this quality-control mechanism may permit the persistence and expansion of dysfunctional clones, thereby increasing susceptibility to tissue degeneration [78]. Consistent with this concept, the accumulation of genetic and epigenetic alterations in aging skin stem/progenitor cells may enable damaged cells to bypass senescence and apoptosis, facilitating the survival and clonal expansion of dysfunctional cells and promoting the development of basal cell carcinoma, squamous cell carcinoma, and melanoma [79, 80]. Importantly, stem-cell aging is not solely cell autonomous but is strongly influenced by niche-derived signals that maintain epigenetic stability and regenerative competence [70]. Emerging evidence suggests that vascular endothelial cells act as signaling niches that regulate epithelial stem-cell quiescence and proliferation through angiocrine factors, indicating that age-related disruption of vascular–epithelial communication may contribute to regenerative decline and tissue dysfunction [81, 82]. Age-related disruption of these signaling networks may further compromise stem-cell function and promote microenvironmental instability, creating conditions that favor senescence propagation and regenerative decline [83]. Collectively, these findings suggest that metabolic cues dynamically shape the epigenetic landscape to coordinate stem-cell fitness, lineage fidelity, and niche interactions, thereby maintaining skin homeostasis. During aging, disruption of this metabolic–epigenetic–niche axis compromises stem-cell function, impairs tissue regeneration, promotes inflammatory signaling and the clonal expansion of dysfunctional cells, ultimately accelerating skin aging and increasing susceptibility to tumor initiation. Immunosenescence–inflammaging axis of skin aging Skin aging is driven by a tightly coupled immunosenescence–inflammaging axis, in which declining immune surveillance and chronic inflammation reinforce each other to sustain tissue dysfunction. Age-associated immunosenescence compromises both innate and adaptive immune functions, leading to impaired recognition and clearance of senescent cells. As a consequence, senescent cells progressively accumulate within the cutaneous microenvironment, undermining immune homeostasis and barrier integrity (Fig. 2).Fig. 2Interplay between inflammaging and immunosenescence in skin aging. Mitochondrial dysfunction and senescent cells promote ROS accumulation and the release of senescence-associated secretory phenotype (SASP) factors, including IL-1β, IL-6, IL-8, IL-18, TNF-α, IFN-γ, and TGF-β. These mediators drive chronic low-grade inflammation (inflammaging), resulting in extracellular matrix degradation, tissue damage, and epidermal barrier dysfunction. Simultaneously, aging-associated immune remodeling leads to immunosenescence, characterized by impaired function of Langerhans cells, macrophages, T cells, and B cells. Inflammaging and immunosenescence interact in a self-reinforcing manner, creating a pathogenic cycle that accelerates the structural and functional deterioration of aged skin. The schematic illustration was created using BioRender (https://www.biorender.com/) Interplay between inflammaging and immunosenescence in skin aging. Mitochondrial dysfunction and senescent cells promote ROS accumulation and the release of senescence-associated secretory phenotype (SASP) factors, including IL-1β, IL-6, IL-8, IL-18, TNF-α, IFN-γ, and TGF-β. These mediators drive chronic low-grade inflammation (inflammaging), resulting in extracellular matrix degradation, tissue damage, and epidermal barrier dysfunction. Simultaneously, aging-associated immune remodeling leads to immunosenescence, characterized by impaired function of Langerhans cells, macrophages, T cells, and B cells. Inflammaging and immunosenescence interact in a self-reinforcing manner, creating a pathogenic cycle that accelerates the structural and functional deterioration of aged skin. The schematic illustration was created using BioRender (https://www.biorender.com/) Concurrently, the persistence of senescent cells gives rise to inflammaging, a chronic, low-grade inflammatory state primarily driven by the SASP. Sustained secretion of pro-inflammatory cytokines, chemokines, and matrix-degrading enzymes not only perpetuates local inflammation but also induces secondary senescence in neighboring cells, thereby amplifying tissue-level degeneration in a feed-forward manner [4]. Beyond senescent cells themselves, non-immune compartments actively contribute to the inflammatory milieu of aged skin. Mitochondrial dysfunction–derived signals, including excessive ROS and cytosolic mitochondrial DNA, activate innate immune pathways such as NF-κB and cGAS–STING, reinforcing pro-inflammatory transcriptional programs [84, 85]. In parallel, age-related extracellular matrix fragmentation generates damage-associated molecular patterns (DAMPs) that further stimulate inflammatory signaling and disrupt fibroblast mechanotransduction [86]. As this inflammatory state persists, chronic cytokine exposure progressively reshapes the cutaneous immune landscape, characterized by reduced naïve T-cell pools, diminished natural killer cell cytotoxicity, and inefficient immune-mediated clearance of senescent fibroblasts [87]. This secondary immune dysfunction further permits senescent cell persistence, thereby sustaining inflammatory output. Through this reciprocal reinforcement, immunosenescence and inflammaging constitute a self-maintaining pathological circuit that accelerates structural degeneration, compromises barrier function, and drives functional decline in aging skin. Microbiome-driven inflammaging Emerging evidence indicates that age-associated microbial dysbiosis is not merely a secondary consequence of aging but also an active driver of inflammaging and progressive skin degeneration [88]. This concept is supported by emerging microbiome-based aging clocks, which associate microbial composition and metabolic function with biological age prediction and age-related physiological decline [89, 90]. Both the skin and gut microbiomes undergo substantial compositional and functional remodeling during aging, characterized by reduced microbial diversity, depletion of beneficial commensals, and expansion of pro-inflammatory taxa. Recent profiling studies demonstrated that aged skin exhibits decreased abundance of Cutibacterium species together with enrichment of Corynebacterium, Streptococcus, and Staphylococcus, changes that are closely associated with impaired barrier integrity, altered sebaceous metabolism, oxidative stress accumulation, and persistent immune activation [88, 91]. In parallel, aging-associated gut dysbiosis is characterized by reduced populations of short-chain fatty acid (SCFA)-producing microorganisms, including Lactobacillus and Akkermansia muciniphila, accompanied by expansion of opportunistic pro-inflammatory bacteria, thereby contributing to systemic immune dysregulation and tissue aging [92]. Mechanistically, microbial dysbiosis promotes inflammaging through interconnected immune, metabolic, and epithelial barrier pathways. Age-related deterioration of intestinal permeability (“leaky gut”) facilitates systemic translocation of microbial-derived pathogen-associated molecular patterns (PAMPs), particularly lipopolysaccharide (LPS). Circulating LPS activates Toll-like receptor 4 (TLR4)/NF-κB signaling, thereby inducing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which amplify SASP and chronic sterile inflammation [93]. Persistent activation of NF-κB further enhances MMP expression, extracellular matrix degradation, and dermal collagen loss, ultimately accelerating wrinkle formation and skin structural decline [94]. Experimental evidence further demonstrated that LPS-induced inflammatory signaling in dermal fibroblasts directly promotes oxidative stress and inflammatory mediator release through NF-κB activation, supporting a mechanistic link between microbial products and cutaneous inflammaging [95]. Moreover, microbial metabolites also critically influence skin aging. SCFAs such as butyrate, acetate, and propionate exert potent anti-inflammatory and immunoregulatory effects by modulating regulatory T-cell differentiation, mitochondrial metabolism, ROS homeostasis, and epithelial barrier maintenance [96, 97]. Aging-associated depletion of SCFA-producing bacteria therefore contributes to immunosenescence, oxidative damage, and chronic inflammation. Importantly, microbial dysbiosis, barrier dysfunction, and immune activation form a self-reinforcing pathogenic loop. Aging-associated alterations in the skin microbiota impair epidermal barrier integrity, while barrier disruption further facilitates microbial imbalance and chronic immune stimulation [98]. This reciprocal interaction perpetuates inflammatory signaling and contributes to sustained inflammaging within the cutaneous microenvironment. Collectively, microbial dysbiosis represents an important upstream driver of the immunosenescence–inflammaging axis. Through disruption of barrier integrity, activation of innate immune signaling, depletion of beneficial microbial metabolites, and modulation of host aging pathways, age-associated microbiome remodeling promotes chronic inflammation and progressive skin degeneration. Innate immune decline Langerhans cells and dermal dendritic cells Langerhans cells (LCs), the major antigen-presenting cells of the epidermis, exhibit markedly reduced migration and antigen-presenting capacity in aged skin, leading to attenuated local immune surveillance. Mechanistically, LC numbers decline, accompanied by diminished secretion of antimicrobial peptides such as human β-defensin 3 and inactivation of IL-1β signaling [99, 100]. Similarly, dermal dendritic cells (DCs), undergo age-associated reductions in both abundance and cytokine release, particularly IL-12 and other pro-inflammatory mediators, thereby weakening the initiation and coordination of adaptive immune responses [101]. Macrophages Macrophage function declines significantly with age, compromising immune surveillance and facilitating the accumulation of senescent cells within the dermal microenvironment [102]. Functionally, M1 macrophages suppress type I collagen synthesis while promoting its fragmentation and degradation in dermal fibroblasts [103]. In contrast, M2 macrophages facilitate collagen production and ECM organization by upregulating structural protein expression [104]. MIF/CD74 signaling, predominantly activated by keratinocytes, suppresses PPAR signaling in fibroblasts, enhances ROS generation, and drives fibroblast senescence by inducing SASP factors [105]. In addition, SPRY1 promotes M1 polarization and elevates proinflammatory mediators such as CAMP and MMP9, thereby exacerbating oxidative stress and dermal tissue degradation [106]. Therapeutically, restoring macrophage homeostasis shows promise. Carnosine, for example, enhances macrophage phagocytic activity and facilitates the clearance of senescent skin cells via activation of the CD36/RAGE–AKT2 signaling axis [107], highlighting a potential intervention strategy to mitigate age-associated immune dysfunction in skin. Mast cells Mast cells (MCs), located in the papillary dermis, are key innate immune sentinels that regulate skin immunity through mediator secretion and effector cell recruitment [108]. Acting as sensors and amplifiers of aging cues, they integrate diverse stimuli, especially SASP factors, to modulate signaling and elicit paracrine effects [109]. Acute activation via receptors such as TLR4 and MRGPRX2 triggers transient MC responses, characterized by the release of granzyme B and perforin, promoting senescent cell clearance and tissue regeneration [110, 111]. However, Notably, acute IL-33 stimulation can activate and reprogram MCs to exacerbate cutaneous inflammation [112]. In contrast, chronic stimuli like UV exposure drive persistent FcεRI-mediated activation in MC cells, sustaining TNF-α, IL-6, IL-1β, and histamine release, which triggers NF-κB signaling, fibroblast senescence, and skin aging [113, 114]. Beyond effector functions, MCs engage in dynamic crosstalk with fibroblasts, keratinocytes, melanocytes, and immune cells to establish self-perpetuating inflammatory and senescent feedback loops. Conversely, through the modulation of Tregs activity, MCs also help restrain excessive inflammation, maintain immune homeostasis, and delay immunosenescence [5]. Collectively, MCs act as dual modulators of skin aging, promoting repair under acute activation yet driving chronic inflammation and senescence under persistent stress. Adaptive immune dysfunction and immune checkpoints T cells undergo profound senescence during skin aging, although their abundance in aged skin remains a subject of debate. Some studies have reported an increased CD4+/CD8+ T cell ratio and higher frequencies of regulatory T cells (Tregs) [115], whereas others found no significant decline in overall T cell density or in the population of CD49a+CD8+ resident memory T cells (Trm) within aged skin [116]. Regulatory T cells (Tregs; CD4+ Foxp3+), which play a pivotal role maintaining immune tolerance, are found to be elevated in aged skin, potentially suppressing protective Th1/Th2 responses and increasing vulnerability to infections or reactivations of latent pathogens, thereby reshaping the inflammatory milieu [117]. Furthermore, UV radiation exacerbates T cell–related immunosenescence by inducing Foxp3+ Tregs and enhancing IL-10 secretion, which further dampens effective immune responses [118]. Senescent T cells typically acquire a pro-inflammatory secretory phenotype, producing ROS and SASP factors that drive inflammaging and accelerate tissue degeneration. In aged skin, dysregulated IL-17 signaling amplifies chronic inflammation, as CD4+ helper, γδ, and innate lymphoid cells shift toward an IL-17–producing state [119]. The PD-1/PD-L1 checkpoint axis serves as a key regulator of immune evasion in aged skin. Upregulated PD-L1 on senescent cells suppresses CD8+ T-cell and NK-cell cytotoxicity, permitting persistence of dysfunctional cells, while reduced PD-1 expression on aged T cells further disturbs immune homeostasis [120]. Targeted therapies of skin aging Epigenetic modulators Epigenetic dysregulation is a key driver of aging-associated transcriptional remodeling in the skin. Targeting epigenetic enzymes, including DNMTs and HDACs, offers a strategy to partially reprogram senescence-associated gene expression. Dihydromyricetin (DHM), a natural flavonoid, inhibits DNMT1 and exerts anti-aging effects in both mouse and human skin models [121]. Similarly, another DNMT1 inhibitor GSK3685032 could combat skin aging and has demonstrated favorable safety and tolerability in vivo [122]. Among histone-modifying enzymes, vorinostat (SAHA), an FDA-approved HDAC inhibitor for cutaneous T-cell lymphoma, attenuates experimental skin aging through suppression of mTOR and NF-κB signaling [84]. Despite these advances, epigenetic drugs often suffer from limited tissue specificity and off-target effects, thereby constraining their translational application. Emerging targets such as m6A and lactylation represent promising but still nascent directions for epigenetic rejuvenation in the skin, underscoring the need for localized and transient epigenetic modulation strategies (Fig. 3, Table 4).Fig. 3Mechanism-based targeted therapeutic strategies for skin aging. Therapeutic approaches for skin aging are organized according to key mechanistic axes. These include epigenetic therapies, senotherapies (comprising senolytics and senomorphics), and mitochondrial therapies. In parallel, biologic therapies focus on cytokine blockade, while immunotherapies include immune checkpoint modulation, CAR-T cell therapy, and vaccines. Finally, regenerative and device-based interventions aim to restore structure and function through tissue regeneration and physical modulation. The schematic illustration was created using BioRender (https://www.biorender.com/)Table 4Skin aging mechanisms and corresponding therapiesAging mechanismCellular targetKey pathwaysTherapiesEpigenetic driftMultiple cellsDNMT, HDAC, m⁶AEpigenetic modulatorsCellular senescenceSenescent subsetsp16, GLS1Senolytics/senomorphicsMitochondrial dysfunctionFibroblasts, keratinocytesSIRT, TRPV, PINK1/ParkinNAD+ boosters, antioxidantsImmunosenescenceT cells, immune surveillance networkPD-1/PD-L1, antigen presentation declineCAR-T, immune checkpoint modulators, vaccinesInflammagingInflammatory mediatorsIL-17, IL-6, TNF-αBiologics Mechanism-based targeted therapeutic strategies for skin aging. Therapeutic approaches for skin aging are organized according to key mechanistic axes. These include epigenetic therapies, senotherapies (comprising senolytics and senomorphics), and mitochondrial therapies. In parallel, biologic therapies focus on cytokine blockade, while immunotherapies include immune checkpoint modulation, CAR-T cell therapy, and vaccines. Finally, regenerative and device-based interventions aim to restore structure and function through tissue regeneration and physical modulation. The schematic illustration was created using BioRender (https://www.biorender.com/) Table 4Skin aging mechanisms and corresponding therapiesAging mechanismCellular targetKey pathwaysTherapiesEpigenetic driftMultiple cellsDNMT, HDAC, m⁶AEpigenetic modulatorsCellular senescenceSenescent subsetsp16, GLS1Senolytics/senomorphicsMitochondrial dysfunctionFibroblasts, keratinocytesSIRT, TRPV, PINK1/ParkinNAD+ boosters, antioxidantsImmunosenescenceT cells, immune surveillance networkPD-1/PD-L1, antigen presentation declineCAR-T, immune checkpoint modulators, vaccinesInflammagingInflammatory mediatorsIL-17, IL-6, TNF-αBiologics Skin aging mechanisms and corresponding therapies Senotherapy Senotherapeutic approaches aim either to eliminate senescent cells (senolytics) or to suppress their secretome (senomorphics), thereby restoring tissue homeostasis to counteract skin aging. Glutaminase 1 (GLS1) has emerged as a critical metabolic vulnerability for senescent cells [123]. Pharmacological inhibition of GLS1 with BPTES disrupts glutaminolysis-dependent pH buffering, selectively inducing senescent cell death and restoring dermal collagen density and reducing MMP and cytokine expression in aged skin models [124]. Classical senolytic agents, including dasatinib plus quercetin (D + Q) [125], and the BCL-2 family inhibitor ABT-263 (Navitoclax), reduce senescent cell burden, suppress SASP factors, improve dermal structure [126]. Notably, ABT263 also reduces melanin synthesis and tyrosinase activity, suggesting a potential role in ameliorating age-related pigmentation [127]. The natural flavonoid fisetin exerts similar senolytic effects by selectively clearing senescent dermal fibroblasts and promoting collagen deposition [128]. Other current characteristic senomorphic agents include β-nicotinamide mononucleotide (NMN) [129], metformin [130], vitamin D₃ or lumisterol derivatives [131] and the mTOR inhibitor rapamycin [132]. Mitochondrial-targeted therapy Mitochondrial dysfunction represents a hallmark of skin aging, leading to oxidative stress, impaired energy metabolism, and ECM degradation [133]. Therapeutic strategies targeting mitochondria primarily focus on (1) antioxidative protection, (2) maintenance of mitochondrial homeostasis and mitophagy, (3) modulation of key signaling pathways, and (4) enhancement of NAD+ metabolism. Mitophagy enhancement represents a particularly robust strategy (e.g. Rosmarinic acid) [134]. Urolithin A, a microbiota-derived metabolite, restores mitochondrial quality control via activation of the SIRT3–FOXO3–PINK1–PARKIN pathway and NRF2 signaling, thereby protecting dermal fibroblasts from UVA-induced damage [135]. In parallel, suppression of aberrant mitochondrial inflammatory signaling such as TRPV1 by nootkatol, Ganoderma lucidum spore oil, and Capsaicin has also shown promise [136–138]; inhibition of the cGAS–STING pathway by salvianolic acid A attenuates UV-induced epidermal thickening and collagen degeneration, linking mitochondrial stress to inflammaging [139]. NAD+ replenishment constitutes another core intervention. CD38 inhibition enhances NAD+ availability, activates sirtuin signaling, and promotes autophagy and mitochondrial biogenesis, collectively improving dermal metabolic resilience [140]. Despite encouraging preclinical evidence, the long-term safety, tissue specificity, and optimal delivery of mitochondrial-targeted anti-skin aging interventions require validation in controlled clinical trials. Immunotherapy Given the central role of T cells in senescent cell regulation and immune surveillance, emerging immunological strategies seek to restore senescent cell surveillance rather than relying solely on pharmacological clearance, offering greater specificity and off-target toxicity. CAR-T therapy Chimeric antigen receptor T-cell (CAR-T) therapy, which involves engineering T-cell surface receptors to recognize specific antigens, has demonstrated remarkable efficacy against malignancies and autoimmune diseases such as systemic lupus erythematosus. Cardiolipin-mimicking lipid nanoparticles (LNPs) have been developed to deliver CAR constructs targeting the senescence- and inflammation-associated antigen urokinase-type plasminogen activator receptor (uPAR), thereby promoting senescent cell clearance and alleviating inflammaging in rheumatoid arthritis models [141]. This approach may enable localized or cyclic CAR expression tailored to tissue-specific compartments, including the skin. Moreover, CRISPR-engineered CAR-T cells targeting intracellular senescence markers such as NKG2DL have safely eliminated senescent cells in primates [142]. However, it is worth noting that skin aging is often accompanied by systemic immunosenescence, which compromises T-cell number and functionality even prior to therapy, thus posing a challenge for CAR-T cell efficacy. Immune checkpoint inhibitors Recent studies also suggest that immune checkpoint inhibitors hold transformative potential in anti-aging therapy. PD-L1⁻ cells remain sensitive to T-cell surveillance, whereas PD-L1+ cells evade immune clearance even in the presence of SASP [143]. Consequently, immune checkpoint blockade targeting PD-L1+ senescent cells may represent a promising strategy for rejuvenation and age-related disease intervention. Intriguingly, rapamycin downregulates PD-L1 expression on senescent fibroblasts, concomitantly reducing SASP factors such as IL-6 and enhancing immune-mediated clearance, thereby linking metabolic regulation to immune checkpoint–dependent senescence surveillance [144]. Anti-aging vaccines DC-based vaccination represents another emerging immunotherapeutic avenue for senescent cell targeting. A cationic protein–conjugated peptide vaccine (Gpnmb-CP) enhances antigen presentation and restores CD8+ T-cell cytotoxicity and memory formation, thereby facilitating the removal of senescent cells [145]. Despite encouraging preclinical outcomes, the clinical translation of anti-aging vaccines requires further optimization in targeting precision, durability, and long-term safety [146]. Modulation of inflammaging via biologics Inflammaging constitutes a central hallmark of skin aging, driven by persistent activation of pro-inflammatory cytokines, including TNF-α, IL-17, IL-23, IL-6, etc. Thus, biologic agents originally developed for inflammatory dermatoses offer a promising opportunity to mitigate inflammation-driven aging processes in the skin. Targeting IL-17 signaling Accumulating evidence indicates that dysregulation of the IL-23/IL-17 axis, a central mediator of cutaneous immune homeostasis, not only underlies the pathogenesis of inflammatory and autoimmune skin disorders but also contributes to age-associated inflammatory remodeling of the skin [119]. Sustained IL-17 signaling promotes keratinocyte dysfunction, amplifies pro-inflammatory cytokine networks, and reinforces senescence-associated structural alterations in the skin. Experimental studies indicate that IL-17 blockade attenuates epidermal inflammation, improves barrier recovery, and enhances wound repair in aged skin [119]. In addition to antibody-based approaches, small-molecule or natural compounds such as Compound K suppress IL-17A- and UVB-induced epidermal aging by inhibiting NF-κB and p38 MAPK signaling [147]. Clinically approved IL-17–targeted biologics, including secukinumab, ixekizumab, and bimekizumab, provide robust proof-of-concept for durable and selective pathway inhibition, highlighting the translational feasibility of targeting IL-17–driven inflammaging. Targeting TNF-α Persistent TNF-α signaling represents a critical molecular link between chronic inflammation, ECM degradation, and fibroblast senescence. By inducing oxidative stress and upregulating MMPs, TNF-α drives hallmark features of skin aging, including collagen loss and dermal structural deterioration [148]. Experimental models consistently demonstrate that inhibition of TNF-α alleviates UV-induced photoaging by suppressing inflammatory mediators and restoring dermal collagen synthesis [149, 150]. Moreover, TNFR2-derived antagonistic peptides exemplify a more selective approach to disrupting TNF-α–TNFR signaling, mitigating inflammation-driven epidermal and dermal aging phenotypes while potentially preserving physiological immune surveillance [150]. The therapeutic tractability of TNF-α is well established in clinical dermatology [151]. The extensive clinical experience with TNF-α blockade in inflammatory skin diseases provides a strong rationale for repurposing these agents to modulate inflammation-driven skin aging [152]. Targeting interleukin-6 IL-6 is a hallmark mediator of systemic and cutaneous inflammaging and is prominently secreted by senescent dermal fibroblasts [153]. Through activation of the JAK/STAT3 pathway, IL-6 reinforces autocrine and paracrine senescence, thereby propagating tissue-level dysfunction during skin aging [154]. Therapeutic blockade of IL-6 signaling effectively suppresses STAT3-driven inflammatory amplification and has demonstrated clinical efficacy across multiple chronic inflammatory diseases [155, 156]. Monoclonal antibodies targeting the IL-6 receptor or IL-6 itself, such as tocilizumab and related agents, underscore the feasibility of selectively modulating this axis [157]. Although direct clinical evidence in skin aging remains limited, the well-established safety profile of IL-6–directed biologics supports their potential repositioning as senomorphic interventions to attenuate inflammaging. Microbiome modulation As the microbiome and its metabolites critically regulate systemic and cutaneous immunity, probiotics, prebiotics (substrates that promote beneficial microbial growth), and postbiotics (bioactive metabolites or fermentation products) represent promising microbiome-targeted anti-aging strategies. Notably, probiotics Lactobacillus plantarum HY7714 and its exopolysaccharides alleviate UV-induced oxidative and matrix damage in fibroblasts, while clinical supplementation significantly improves hydration, elasticity, and wrinkle outcome [92]. Similarly, promising skin-rejuvenating results have also been seen in the usage of probiotics Streptococcus thermophilus TCI633 [158], Bifidobacterium longum 68S [159]. Notably, postbiotic formulations such as T. thermophilus/B. subtilis ferment [160], Streptococcus spp. supernatants [160], and Epidermidibacterium keratini ferment filtrate enriched with orotic acid [161] have demonstrated improvements in wrinkle reduction and skin elasticity. Collectively, these findings suggest that microbiome is a potential therapeutic target for precision rejuvenation strategies for skin aging. Lifestyle modifications Healthy lifestyle, including proper nutrition, calorie restriction, regular exercise, adequate sleep, and stress management, plays a key role in preventing and slowing skin aging by reducing oxidative stress, inflammation, and promoting skin regeneration. Nutritional interventions have emerged as a promising strategy for promoting healthy skin aging. Dietary patterns rich in antioxidants, polyphenols, and unsaturated fatty acids, particularly the Mediterranean diet, can reduce oxidative stress and chronic inflammation, two key drivers of cutaneous aging [162]. Moreover, bioactive compounds such as tea polyphenols, curcumin, flavonoids, and silymarin exhibit antioxidant and photoprotective effects, helping to attenuate UV-induced damage, collagen degradation, and wrinkle formation [163, 164]. Together, these findings suggest that nutritional interventions may preserve skin homeostasis and mitigate both intrinsic aging and photoaging. Calorie restriction (CR), defined as reduced caloric intake without malnutrition, is one of the most extensively studied non-pharmacological interventions for delaying aging [165]. In skin, experimental studies have shown that CR reduces the age-related accumulation of advanced glycation and glycoxidation products, including Nε-(carboxymethyl)lysine and pentosidine, thereby limiting collagen crosslinking, dermal stiffening, and extracellular matrix dysfunction [166, 167]. CR has also been associated with reduced wrinkle formation and preservation of epidermal stem cell function, partly through restoration of age-related circadian dysregulation [168,169]. Collectively, these findings suggest that CR may mitigate both structural and functional hallmarks of skin aging. However, its long-term efficacy and feasibility in humans remain to be established. Exercise represents an effective lifestyle intervention for mitigating inflammaging and improving skin health. Aerobic exercise has been shown to reduce circulating inflammatory mediators [170], while both aerobic training (AT) and resistance training (RT) positively impact skin elasticity and the upper dermal structure. Importantly, RT additionally enhances dermal thickness, potentially through increased dermal biglycan expression and reduced circulating levels of CCL28, N,N-dimethylglycine, and CXCL4 [171]. Collectively, these findings suggest that regular exercise may attenuate structural and inflammatory features of skin aging by promoting dermal remodeling and maintaining cutaneous homeostasis (Table 5).Table 5Therapeutic strategies for skin aging and their translational development statusTherapyRepresentative therapiesMechanisms relevant to skin agingDevelopment stageEpigenetic modulatorsDihydromyricetin (DHM), GSK3685032, Vorinostat (SAHA)Reverse age-associated epigenetic dysregulation, suppress senescence-associated transcriptional remodeling and inflammagingPreclinical; SAHA approved for other indicationsSenotherapyBPTES, Dasatinib + Quercetin (D + Q), ABT-263 (Navitoclax), Fisetin, NMN, Metformin, Vitamin D₃/Lumisterol derivatives, RapamycinEliminate senescent cells or suppress SASP, thereby reducing chronic inflammation, collagen degradation, and age-related tissue dysfunctionPredominantly preclinical; metformin/rapamycin/fisetin: clinical evaluationMitochondrial-targeted therapiesRosmarinic acid, Urolithin A, Nootkatol, Ganoderma lucidum spore oil, Capsaicin, Salvianolic acid A, CD38 inhibitorsImprove mitochondrial homeostasis and mitophagy, enhance NAD+ metabolism, and reduce oxidative stress and inflammagingPrimarily preclinicalImmunotherapySenescence-targeted CAR-T cells, PD-L1 immune checkpoint blockade, Gpnmb-CP vaccineEnhance immune surveillance and clearance of senescent cells, thereby mitigating inflammaging and tissue dysfunctionPreclinicalAnti-inflammaging biologicsIL-17 inhibitors (Secukinumab, Ixekizumab, Bimekizumab), TNF-α inhibitors, IL-6 inhibitors (Tocilizumab)Suppress pro-inflammatory cytokine signaling, attenuate inflammaging, fibroblast senescence, and extracellular matrix degradationClinically approved for inflammatory diseases; repurposing for skin aging remains investigationalMicrobiome modulationProbiotics (Lactobacillus plantarum HY7714, Streptococcus thermophilus TCI633, Bifidobacterium longum 68S), prebiotics, postbioticsRestore microbial homeostasis, strengthen barrier function, and reduce oxidative stress and chronic inflammationPreclinical to early clinicalLifestyle modificationsMediterranean diet, calorie restriction, aerobic exercise, resistance trainingReduce oxidative stress and inflammaging, preserve collagen and stem cell function, and promote dermal remodelingClinical and epidemiological evidence Table 5Therapeutic strategies for skin aging and their translational development statusTherapyRepresentative therapiesMechanisms relevant to skin agingDevelopment stageEpigenetic modulatorsDihydromyricetin (DHM), GSK3685032, Vorinostat (SAHA)Reverse age-associated epigenetic dysregulation, suppress senescence-associated transcriptional remodeling and inflammagingPreclinical; SAHA approved for other indicationsSenotherapyBPTES, Dasatinib + Quercetin (D + Q), ABT-263 (Navitoclax), Fisetin, NMN, Metformin, Vitamin D₃/Lumisterol derivatives, RapamycinEliminate senescent cells or suppress SASP, thereby reducing chronic inflammation, collagen degradation, and age-related tissue dysfunctionPredominantly preclinical; metformin/rapamycin/fisetin: clinical evaluationMitochondrial-targeted therapiesRosmarinic acid, Urolithin A, Nootkatol, Ganoderma lucidum spore oil, Capsaicin, Salvianolic acid A, CD38 inhibitorsImprove mitochondrial homeostasis and mitophagy, enhance NAD+ metabolism, and reduce oxidative stress and inflammagingPrimarily preclinicalImmunotherapySenescence-targeted CAR-T cells, PD-L1 immune checkpoint blockade, Gpnmb-CP vaccineEnhance immune surveillance and clearance of senescent cells, thereby mitigating inflammaging and tissue dysfunctionPreclinicalAnti-inflammaging biologicsIL-17 inhibitors (Secukinumab, Ixekizumab, Bimekizumab), TNF-α inhibitors, IL-6 inhibitors (Tocilizumab)Suppress pro-inflammatory cytokine signaling, attenuate inflammaging, fibroblast senescence, and extracellular matrix degradationClinically approved for inflammatory diseases; repurposing for skin aging remains investigationalMicrobiome modulationProbiotics (Lactobacillus plantarum HY7714, Streptococcus thermophilus TCI633, Bifidobacterium longum 68S), prebiotics, postbioticsRestore microbial homeostasis, strengthen barrier function, and reduce oxidative stress and chronic inflammationPreclinical to early clinicalLifestyle modificationsMediterranean diet, calorie restriction, aerobic exercise, resistance trainingReduce oxidative stress and inflammaging, preserve collagen and stem cell function, and promote dermal remodelingClinical and epidemiological evidence Therapeutic strategies for skin aging and their translational development status Conclusion Early studies of skin aging primarily emphasized structural deterioration and focused on separated processes such as fibroblast dysfunction and extracellular matrix degradation. While these foundational insights established the morphological hallmarks of aged skin, they provided limited explanation for the progressive, self-reinforcing nature of skin aging. Over the past decade, the field has undergone a conceptual shift toward viewing skin aging as a dynamic, multilevel process governed by epigenetic drift, cellular senescence, mitochondrial dysfunction, and age-associated immune and inflammatory dysregulation that collectively impair tissue homeostasis. In this emerging framework, skin aging is increasingly recognized as a failure of tissue homeostasis driven by tightly interconnected metabolic–epigenetic–immune networks operating across cellular, niche, and tissue levels. Epigenetic remodeling integrates environmental and metabolic cues to reprogram cellular identity; mitochondrial dysfunction amplifies oxidative stress and bioenergetic insufficiency; and the accumulation of senescent cells reshapes the cutaneous microenvironment through chronic inflammatory signaling and immune imbalance. Moreover, heterogeneous senescent cell states and spatially organized aging niches disrupt intercellular communication and regenerative capacity, while microbiome dysbiosis further reinforces inflammaging through alterations in barrier function, microbial metabolites, and immune surveillance. Together, these processes establish a self-sustaining immunosenescence–inflammaging axis that accelerates tissue degeneration and compromises regenerative capacity. Concomitantly, therapeutic strategies for skin aging have evolved from largely symptomatic or cosmetic interventions toward mechanism-guided approaches. Epigenetic and mitochondrial modulators aim to restore transcriptional and metabolic equilibrium; senolytics and senomorphics selectively eliminate or reprogram senescent cells; biologics and immunotherapies represent a critical step toward precision senotherapy by targeting dysregulated immune and inflammatory pathways; microbiome-targeted interventions seek to restore immune and metabolic homeostasis and regenerative and device-based therapies seek to reactivate endogenous repair programs and tissue remodeling. Importantly, these modalities reflect not isolated advances but a broader shift toward targeting the upstream regulatory networks that govern aging trajectories. Despite these advances, several key challenges remain. The identification of reliable, skin-specific biomarkers capable of capturing senescence heterogeneity and functional aging states is still lacking. Moreover, the long-term safety and systemic consequences of extensive senescent-cell clearance warrant careful evaluation, particularly given the context-dependent beneficial roles of senescence in tissue repair and tumor suppression. Looking forward, the integration of multi-omics, spatially resolved technologies, and longitudinal human studies will be critical for mapping the regulatory networks underlying skin aging and for stratifying patients based on molecular aging profiles. Ultimately, the future of anti-skin aging lies not in delaying chronological aging, but in achieving precision rejuvenation through the rational combination of molecular, metabolic, immune, and regenerative strategies to restore cellular plasticity, tissue resilience, and functional integrity of the skin.